News
-
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
May 7, 2026 -
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
May 6, 2026 -
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
May 5, 2026 -
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
April 30, 2026 -
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
April 28, 2026 -
Aclarion Announces $2.5 Million Stock Repurchase Plan
April 22, 2026 -
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
April 16, 2026 -
Aclarion Receives Pinnacle Award for AI Innovation
April 14, 2026 -
Aclarion Announces Agreement with Weill Cornell Medicine
April 8, 2026 -
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
April 7, 2026